DDInter1676 DDInter1698
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or
Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan was granted FDA approval on 28 August 2020.
Somapacitan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Somapacitan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapsone
Somapacitan {u} may lead to a major life threatening interaction when taken with {v} Bexarotene
Somapacitan may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Dapsone
Somapacitan may lead to a major life threatening interaction when taken with Bexarotene